Exploring Clinical Updates in HR+/HER2- Breast Cancer Treatment and the Impact on Patient Care

Add-on activity

This activity includes a patient perspective.

Program Description

CDK4/6 inhibitors are an important first-line treatment for patients with metastatic hormone receptor-positive (HR+) breast cancer and are emerging as a treatment option in the adjuvant setting. This program will review long-term data for available CDK4/6 inhibitors and how these results may shape considerations for novel strategies in the use of these agents. Pharmacists should be aware of the potential role of novel selective estrogen receptor down-regulators (SERDs). The increase in utilization of oral oncolytics offers increased opportunities for pharmacists to improve the way these products are prescribed, dispensed, administered, and monitored. Oncology pharmacists are actively involved in the management of drug therapies for patients receiving treatment with CDK4/6 inhibitors and should be aware of toxicities and dose adjustments required. Additionally, faculty experts will share solutions to address nonadherence and counseling pearls for patients receiving CDK4/6 inhibitors. A patient perspective interview is included throughout the program, highlighting the experience of a patient with HR+ breast cancer in navigating diagnosis and treatment.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: August 31, 2022
Expiration date: February 29, 2024

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Dissect emerging investigational approaches and long-term follow-up data for hormone receptor-positive (HR+) breast cancer treatment strategies
• Explore recent data supporting and investigating the use of cyclin-dependent kinase 4/6 inhibitors for the treatment of HR+/human epidermal growth factor receptor 2-negative breast cancer in the adjuvant setting
• Apply management and monitoring recommendations to therapeutic treatment strategies to support outcomes and quality of life in patients with HR+ breast cancer

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-404-H01-P. The activity is available for CE credit through February 29, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Danielle Roman, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Amy L. Morris, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms